STOCK TITAN

Voyager Therapeutics Inc - VYGR STOCK NEWS

Welcome to our dedicated news page for Voyager Therapeutics (Ticker: VYGR), a resource for investors and traders seeking the latest updates and insights on Voyager Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Voyager Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Voyager Therapeutics's position in the market.

Rhea-AI Summary
Voyager Therapeutics, Inc. (Nasdaq: VYGR) announces a strategic collaboration and capsid license agreement with Novartis Pharma AG, a subsidiary of Novartis AG (NYSE: NVS) to advance potential gene therapies for Huntington’s disease (HD) and spinal muscular atrophy (SMA). Voyager will receive $100 million up-front and is eligible for up to $1.2 billion in milestone payments and tiered royalties. Novartis will pay Voyager $100 million, including a $20 million purchase of newly issued equity, and is eligible to receive milestone payments and tiered royalties on global net sales of products incorporating Voyager’s TRACER capsids.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.64%
Tags
none
-
Rhea-AI Summary
Voyager Therapeutics, Inc. (Nasdaq: VYGR) has announced the selection of a lead development candidate for its superoxide dismutase 1 (SOD1)-mutated amyotrophic lateral sclerosis (ALS) gene therapy program. The company anticipates filing an investigational new drug (IND) application with the FDA for the candidate in mid-2025. The candidate has shown a 73% reduction of SOD1 in cervical spinal cord motor neurons in a non-human primate study, with an ability to transduce both neurons and astrocytes. Data previously shared at the 2022 ASGCT annual meeting demonstrated an increase in survival by a median of 152 days in a G93A mouse model.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.28%
Tags
none
-
Rhea-AI Summary
Voyager Therapeutics reported Q3 2023 financial and operating results, highlighting the initiation of GLP toxicology studies for their anti-tau antibody VY-TAU01 and progress in their SOD1 ALS gene therapy program. The company expects to file an IND for VY-TAU01 in 1H 2024 and select a development candidate for the SOD1 ALS program by the end of the year. Voyager also mentioned multiple opportunities for INDs in 2025 across their pipeline.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.08%
Tags
earnings
Rhea-AI Summary
Voyager Therapeutics, a biotechnology company, will report its Q3 2023 financial and operating results on November 6, 2023. A conference call and webcast will be held to review the results. Telephone participants can register in advance to receive a confirmation email with details on how to join the call. The webcast will be available on the Voyager website, and a replay will be available for at least 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.03%
Tags
earnings
-
Rhea-AI Summary
Voyager Therapeutics CEO to present at Chardan conference on Oct 2
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.66%
Tags
conferences
-
Rhea-AI Summary
Voyager Therapeutics grants non-qualified stock options and restricted stock units to new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.11%
Tags
none
Rhea-AI Summary
Voyager Therapeutics to participate in investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.69%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.8%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.92%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.44%
Tags
earnings
Voyager Therapeutics Inc

Nasdaq:VYGR

VYGR Rankings

VYGR Stock Data

505.54M
36.95M
17.33%
48.8%
4.26%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Cambridge

About VYGR

voyager therapeutics is a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (cns). voyager is committed to advancing the field of aav (adeno-associated virus) gene therapy through innovation and investment in vector optimization and engineering, dosing techniques, as well as process development and production. the company’s initial pipeline is focused on cns diseases in dire need of effective new therapies, including parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (als), and friedreich’s ataxia. founded by scientific and clinical leaders in the fields of aav gene therapy, expressed rna interference and neuroscience, voyager therapeutics was launched in 2014 with funding from leading life sciences investor third rock ventures and is headquartered in cambridge, mass. for more information, please visit www.voyagertherapeutics.com.